Sarcopenia, lung disease and mortality: a secondary analysis of the CRELES study

• Autor(a) principal: Borda,Miguel Germán
• Data de Publicação: 2019
• Outros Autores: Patino-Hernandez,Daniela, Cano-Gutiérrez,Carlos Alberto, Celis-Preciado,Carlos Andrés, Pérez-Zepeda,Mario Ulises
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Geriatrics, Gerontology and Aging (Online)
• Texto Completo: https://ggaging.com/details/513
• topic: sarcopenia; chronic obstructive pulmonary disease; mortality; aged.

<p><b>AIM:</b> Chronic obstructive pulmonary disease (COPD) is a pro-inflammatory condition leading to wasting states such as sarcopenia. We aimed to describe the effect of COPD and sarcopenia on mortality in Costa Rican older adults in the Costa Rican Longevity and Healthy Aging Study (CRELES).<br> <b>METHOD:</b> This is a secondary analysis of the CRELES, a cohort study consisting of three waves of interviews. For the current study, data from the first and third waves were used. The dependent variable was survival status. COPD and sarcopenia were independent variables. Bivariate analyses were used to compare mortality curves for each group. Association with 3-year mortality was tested with Cox regression models, and hazard ratios (HR) with 95% confidence intervals (CI) were estimated as a measure of the strength of association.<br> <b>RESULTS:</b> Of a total of 2704 participants, 54.29% (n = 1468) were women. Overall mortality was 9.05%. Sarcopenic older adults had the strongest association with mortality (HR = 2.65; 95%CI, 1.81–3.90; p &lt; 0.001), followed by those with both COPD and sarcopenia (HR = 2.59; 95%CI, 1.37–4.92; p = 0.003). The weakest association with mortality was found in patients with neither COPD nor sarcopenia. CONCLUSIONS: The synergistic effect of sarcopenia and COPD has been shown to independently increase mortality in older patients. Our results may be applicable to both Latin American residents and subjects of Hispanic descent living in developed countries. Sarcopenia should be assessed in all patients with COPD since the latter is not a disease limited to the lungs, but rather a systemic disease.</p>